We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
-9%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$353M
AUM Growth
+$12.9M
Cap. Flow
+$60.9M
Cap. Flow %
17.29%
Top 10 Hldgs %
42.16%
Holding
101
New
22
Increased
19
Reduced
17
Closed
34

Top Buys

Rank Stock Value
1
BHVN icon
Biohaven
BHVN
+$8.16M
2
RXST icon
RxSight
RXST
+$7.8M
3
ESTA icon
Establishment Labs
ESTA
+$7.58M
4
CAPR icon
Capricor Therapeutics
CAPR
+$7.52M
5
CMPS
Compass Pathways
CMPS
+$7.22M

Top Sells

Rank Stock Value
1
VERA icon
Vera Therapeutics
VERA
+$11.2M
2
PCVX icon
Vaxcyte
PCVX
+$8.23M
3
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$6.49M
4
IRTC icon
iRhythm Holdings
IRTC
+$6.38M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$5.27M

Sector Composition

Rank Sector Weight
1 Healthcare 91%
2 Consumer Staples 0.08%
3 Consumer Discretionary 0%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FATBW
76
DELISTED
FAT Brands Inc. Warrant
FATBW
– –
-200,000
Closed -$499K
GPCR icon
77
Structure Therapeutics
GPCR
$3.78B
– –
-70,000
Closed -$3.07M
IRTC icon
78
iRhythm Holdings
IRTC
$4.2B
– –
-86,000
Closed -$6.38M
NEXRW
79
Nexera Technologies Ltd Warrant
NEXRW
$48.9K
– –
-68,681
Closed -$2.44K
MIST icon
80
Milestone Pharmaceuticals
MIST
$152M
– –
-440,000
Closed -$669K
MLTX icon
81
MoonLake Immunotherapeutics
MLTX
$1.55B
– –
-40,000
Closed -$2.02M
MOBXW icon
82
Mobix Labs Warrants
MOBXW
$752K
– –
-150,000
Closed -$22.3K
NLSPW
83
DELISTED
NLS Pharmaceutics Warrant
NLSPW
– –
-200,000
Closed -$2.28K
NXGLW icon
84
NexGel Inc Warrant
NXGLW
– –
-225,000
Closed -$91.5K
NXLIW
85
DELISTED
Nexalin Technology Inc Warrant
NXLIW
– –
-105,000
Closed -$8.4K
OCGN icon
86
Ocugen
OCGN
$434M
– –
-2,350,000
Closed -$2.33M
ONFOW icon
87
Onfolio Holdings Warrant
ONFOW
$64.5K
– –
-200,000
Closed -$34K
OTLK icon
88
Outlook Therapeutics
OTLK
$191M
– –
-541,549
Closed -$2.89M
PCVX icon
89
Vaxcyte
PCVX
$8.64B
– –
-72,000
Closed -$8.23M
RCKTW icon
90
Rocket Pharmaceuticals Warrant
RCKTW
$288K
– –
-731,561
Closed -$51.2K
REAL icon
91
The RealReal
REAL
$1.5B
– –
-1,270,000
Closed -$3.99M
SRZNW icon
92
Surrozen Inc Warrant
SRZNW
$8.86K
– –
-82,233
Closed -$1.04K
TPST icon
93
Tempest Therapeutics
TPST
$14.6M
– –
-41,923
Closed -$763K
VCEL icon
94
Vericel Corp
VCEL
$2.31B
– –
-68,000
Closed -$2.87M
WLDSW icon
95
Wearable Devices Ltd Warrant
WLDSW
$132K
– –
-1,961
Closed -$28.1K
XPON icon
96
Expion360
XPON
$3.31M
– –
-1,715
Closed -$106K
VSEEW
97
DELISTED
VSEE HEALTH INC WTS 29
VSEEW
– –
-150,000
Closed -$6K
CYCUW
98
Cycurion Inc Warrant
CYCUW
$311K
– –
-100,000
Closed -$2.18K
TCBPW
99
DELISTED
TC BioPharm (Holdings) plc Warrants
TCBPW
– –
-18,823
Closed -$343
MITAW
100
DELISTED
Coliseum Acquisition Corp. Warrant
MITAW
– –
-28,333
Closed -$1.42K
1 2 3
4
5

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
ICP
Indus Capital Partners New York $39.7M AUM 53.95% 1-Year Est. Return

Altium Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Altium Capital Management held 101 positions worth $353M, up 3.8% from $340M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Altium Capital Management deployed $60.9M of net new capital in Q4 2024, opening 22 new positions and adding to 19 existing holdings. Its largest new stake was Compass Pathways: 1,424,400 shares worth $5.38M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 97% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was Vera Therapeutics, an estimated $11.2M trimmed.

  • Altium Capital Management's largest Q4 2024 buy was Compass Pathways: 1,424,400 shares worth $5.38M.
  • Altium Capital Management added most to Biohaven in Q4 2024, an estimated $8.16M increase.
  • Altium Capital Management's biggest Q4 2024 reduction was Vera Therapeutics, cutting an estimated $11.2M.
  • Altium Capital Management fully exited Vaxcyte in Q4 2024, selling an estimated $8.23M.
  • Altium Capital Management's ten largest holdings make up 42% of its $353M portfolio in Q4 2024.
  • Altium Capital Management opened 22 new positions and closed 34 in Q4 2024.
  • Altium Capital Management's portfolio value rose 3.8% quarter-over-quarter to $353M.

Based on Altium Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.